Transcript Ohio Advocacy Forum APhA

National Pharmacy
Advocacy Updates
September 23, 2016
2nd Ohio
Pharmacy
Advocacy
Forum
Stacie Maass, Sr. V.P., Pharmacy Practice
and Government Affairs
American Pharmacists Association
LEGISLATIVE UPDATE
2
Patient Access to Pharmacists’ Care Coalition (PAPCC)
H.R.592 / S.314
Pharmacy and Medically Underserved Areas
Enhancement Act
•
Representatives Brett Guthrie (R-KY), G.K. Butterfield (DNC), Todd Young (R-IN), and Ron Kind (D-WI)
introduced on January 28, 2015
– Currently 292 cosponsors, more than 65% of the
House
–
•
•
C
Senators Chuck Grassley (R-IA), Sherrod Brown (D-OH),
Robert Casey (D-PA), and Mark Kirk (R-IL) introduced
on January 29, 2015
– Currently 50 supporters, 50% of the Senate
Amends section 1861 of the Social Security Act to
recognize pharmacists’ services within Medicare Part B
No. of Cosponsors
H.R. 592 – 292
S. 314 – 49
Bipartisan Support
(as of 9/10/16)
3
PAPCC
H.R.592 / S.314 – Scope of Proposal
• Pharmacists – State-licensed pharmacists with a B.S. Pharm. or
Pharm. D. degree who may have additional training and
certificates depending on state laws
• Services – Services authorized under state pharmacy scope of
practice laws
• Patients – Services provided in/ for Medically Underserved Areas
(MUA), Medically Underserved Populations (MUP), or Health
Professional Shortage Areas (HPSA)
No impact on state
scope of practice
4
PAPCC
Nearly 40 organizations and growing!
5
Successes – A lot of which to Proud
• Pharmacy unified in support
• Formed a results-oriented coalition that continues to grow
– State Pharmacy Associations became members
• Legislation has support from over 67% of the House, 50% of the
Senate
• Support is bipartisan
– Remarkable for health care legislation in a partisan Congress
– Support from members of Congress who are health care
providers
• After almost 3 years, involving 2 sessions of Congress, no
opposition to legislation
6
PAPCC Next Steps
•
Focused on obtaining CBO score and a hearing in the House
– Update –
•
•
•
•
•
•
•
CBO
Hearing
Meeting with Rep Guthrie
Congressional Calendar for 2016
Tool Development - Heat maps by National Minority Quality Forum
(NMQF)
Membership
Preparing for 2017
7
APhA investment/ collaborations
• Invested over $3 Million to Provider Status initiative
– This does not include operational costs
• Wouldn’t be successful without the contributions of state
pharmacy associations, organizations and pharmacists
– Synergistic effects at state and federal levels
o State efforts helped our work at the federal level
• Appreciate feedback on current resources and needs
o Need – Information on pharmacists’ outcomes
• Information on payers covering pharmacists’ services
• Research demonstrating positive outcomes
• Sustain the excitement
8
Prescription Drug Abuse
•
•
Comprehensive Addiction and Recovery Act (CARA)
–
Passed by Congress and signed into law July 2016
–
APhA worked with members of the House and Senate on numerous issues related to the
pharmacists role, such as naloxone access, patient and provider education, prescription
drug monitoring programs, partial fills, medication-assisted treatment, guideline
development, and standing-order incentives
CDC Prescribing Guideline
–
Finalized in March 2016
–
APhA comments acknowledged the need for ongoing, additional research and expressed
our support of efforts to address the opioid epidemic and CDC’s recommendation that
physicians engage in collaborative practice models with pharmacists
9
Prescription Drug Abuse (cont.)
•
•
•
•
Medication-assisted treatment (MAT): APhA suggested that SAMHSA increase the amount of
patients that physicians can treat with buprenorphine, discussed the pharmacists role in providing
MAT
Naloxone: States have been passing legislation and regulations to expand access to naloxone
through the use of collaborative practice agreements, standing orders and state-based protocols
– FDA has signaled that it is considering OTC naloxone as it is in early stages of developing a
labeling framework that is more patient-friendly than current standards
Labeling: FDA mandated class-wide changes, including boxed warnings, to drug labeling,
including patient information, regarding risks associated with the combined use of certain opioids
medications and benzodiazepines
Education: APhA provided feedback to HHS’s request for information regarding prescriber
education
–
Comments emphasized that pharmacists, in some circumstances prescribe opioids, the growing role
of the pharmacist in helping curb opioid abuse while maintaining patient access, and highlighted
APhA’s educational offerings regarding opioid abuse, pain management and treatment
10
REGULATORY UPDATE
11
Value-Based Purchasing
MACRA
•
•
•
On May 9, 2016, CMS issued a proposed rule to transition away from fee-for-service
(FFS) and the sustainable growth rate (SGR) formula to paying for value - Merit-based
incentive payment system (MIPS) or Advanced Alternative Payment Models (APMS) in
2019. Final rule scheduled to be released November 1
CMS will measure physicians on 4 categories: Quality, Advancing Care Information,
CPIA, Activities and Cost
On September 8, CMS announced Year 1 flexibility for Quality Payment Program (QPP)
reporting:
–
–
–
–
•
First Option: Test the QPP (No Penalty)
Second Option: Participate for part of the calendar year (Qualify for Small Payment
Adjustment)
Third Option: Participate for the full calendar year (Qualify for Incentives/Penalties)
Fourth Option: Participate in an Advanced Alternative Payment Model in 2017 (Qualify
for 5% adjustment)
APhA urged CMS to remove barriers preventing pharmacists’ inclusion in Medicare
(not-currently recognized as “eligible clinicians”)and their contributions to quality
12
Value-Based Purchasing
Physician Fee Schedule (PFS)
•
On July 15, CMS released the annual proposed rule that outlines how Medicare pays
physicians
•
Based on feedback from APhA work groups on chronic care management (CCM) and
diabetes, in its comments, APhA urged CMS to:
– Continue efforts provide more flexibility regarding the billing of CCM to encourage
participation and utilization
– Clarify and provide education and training for its staff regarding the role of pharmacists
in delivering Diabetes Self-Management Training (DSMT) services
• CMS and Medicare Administrative Contractors (MACs) often incorrectly reject DSMT
claims because of the misunderstanding that pharmacists are not permitted to
provide these services since they are not recognized providers under Part B
– Allow for more flexibility in practitioner billing for additional hours of DSMT for complex
beneficiaries and increase payments under existing DSMT codes
– Seek mechanisms to appropriately attribute the role of the pharmacists in patient care
services and in quality (e.g., through measures and payment codes)
– Increase transparency regarding Medication Therapy Management (MTM) services within
MA-PD and Part D plans
13
Value-Based Purchasing (cont.)
Part B Demo
•
On March 8, CMS issued a proposed rule announcing a Part B demonstration project for Rx
drugs (would impact rheumatology/cancer drugs costing $480/per day the most); CBO
scores expected in “several weeks” and possible final rule this month
•
Phase 1: Focused on changing the drug pricing structure - implementing a variation of the
average sale price (ASP) add-on payment - ASP + 6% (control) and ASP + 2.5 % and Flat Fee
Drug Payment ($16.50 per drug/per day)
•
Phase 2: Focused on value-based purchasing models (January 2017)
– ASP +2.5% + Flat Fee Drug Payment with VBP Tools:
•
•
•
•
•
•
Discounting or eliminating patient cost-sharing
Feedback on prescribing patterns and online decision support tools
Indications-based pricing
Reference pricing
Risk-sharing agreements based on outcomes
APhA highlighted the following concerns in its comments: the negative impact to patient
access, narrow distribution networks may result; the failure to mention pharmacists/
medication experts on the team; and savings attributed may not be real as increases in other
areas (e.g., Part D)
14
Value-Based Purchasing (cont.)
Enhanced MTM Model
•
On September 28, 2015, CMS announced an enhanced MTM model under Part D set to
begin on January 1, 2017
– Model has a five-year performance period, in 5 Part D regions: Region 7 (Virginia), Region
11 (Florida), Region 21 (Louisiana), Region 25 (Iowa, Minnesota, Montana, Nebraska,
North Dakota, South Dakota, Wyoming), and Region 28 (Arizona)
– Goal is to assess whether providing selected Medicare Prescription Drug Plans (PDPs) with
additional incentives and flexibilities to design and implement innovative programs will
better achieve the overall goals for MTM programs, including:
• Improving compliance with medication protocols, including high-cost drugs;
• Ensuring that beneficiaries get the medications they need, and they are used properly;
• Reducing medication-related problems, such as duplicative or harmful prescription drugs, or
suboptimal treatments;
• Increasing patients’ knowledge of their medications to better achieve their or their
prescribers’ goals of therapy; and
• Improving communication among prescribers, pharmacists, caregivers and patients
– Note: Part D MTM requires multiple chronic diseases, multiple Part D drugs, and annual
Part D drug spend that meet or exceed a threshold of $3,919
15
Recent Compounding Activities
•
•
•
•
On April 15, FDA released 3 draft guidance documents related to DQSA:
– Prescription Requirement Under Section 503A (prohibits office use under 503A)
– Hospital and Health System Compounding
– Facility Definition Under Section 503B
On July 8, FDA released 2 additional draft guidance documents:
– Compounded Drug Products That Are Essentially Copies of a Commercially Available
Drug Product Under Section 503A
– Compounded Drug Products That Are Essentially Copies of Approved Drug Products
Under Section 503B
On July 12, FDA issued a “notice” of a new procedure for inspections of human drug
compounders.
• Agency will determine if compounders are 503A facilities before applying CGMPs.
On August 4, FDA released a draft guidance document on Insanitary Conditions at
Compounding Facilities
16
Recent Compounding Activities
•
•
•
•
On April 15, FDA released 3 draft guidance documents related to DQSA:
– Prescription Requirement Under Section 503A (prohibits office use under 503A)
– Hospital and Health System Compounding
– Facility Definition Under Section 503B
On July 8, FDA released 2 additional draft guidance documents:
– Compounded Drug Products That Are Essentially Copies of a Commercially Available
Drug Product Under Section 503A
– Compounded Drug Products That Are Essentially Copies of Approved Drug Products
Under Section 503B
On July 12, FDA issued a “notice” of a new procedure for inspections of human drug
compounders.
• Agency will determine if compounders are 503A facilities before applying CGMPs.
On August 4, FDA released a draft guidance document on Insanitary Conditions at
Compounding Facilities
17
Recent Compounding Activities
FDA released 3 draft guidance documents related to DQSA in April, 2016
1. Prescription Requirement Under Section 503A
• Prohibits office use under 503A
• Limits anticipatory compounding to a 30-day supply
• Attempts to define what constitutes a valid prescription
2. Hospital and Health System Compounding
• Allows hospitals and health systems to distribute compounded drug
products, without patient-specific prescriptions, for up to a 1-mile radius
from their pharmacy within their own facilities
3. Facility Definition Under Section 503B
• APhA urged FDA in its comments (which were due July) to return to its previous
interpretation of 503A in which office use was allowed
18
Recent Compounding Activities
FDA issued Draft Guidance on Compounded Drug Products that Are Essentially Copies of a
Commercially Available Drug Product Under Section 503A in July, 2016; comments due Oct 6
•
Determination of a Commercially Available Drug: “the compounded drug product has the same
active pharmaceutical ingredient(s) (API) as the commercially available drug product; the API(s)
have the same, similar, or an easily substitutable dosage strength; and the commercially
available drug product can be used by the same route of administration as prescribed for the
compounded drug, unless a prescriber determines that there is a change, made for an identified
individual patient, which produces for that patient a significant difference from the commercially
available drug product”
•
Significant Difference Exceptions: API (Inactive Ingredients); Drug Strength (i.e., Same, Similar or
Easily Substitutable Strength) - within 10% of the strengths of the respective commercially
available products; Same Route of Administration (e.g., Topical, Intravenous, Oral) – regardless of
how labeled
•
Regularly/Inordinate Compounded Amounts: No action “if the compounder fills four or fewer
prescriptions for the relevant compounded drug product in a calendar month”
19
Recent Compounding Activities
FDA released a “notice” document on July 12, 2016
• New Procedure for Inspections of Human Drug Compounders
– Agency will determine if compounders are 503A facilities before applying
CGMPs
– Effective August 1 (and does not apply to current or past inspections)
– FDA intends to continue to inspect compounding facilities and to take
action, as appropriate, when the agency identifies violations of Federal law
that could put patients at risk
– FDA will still undertake inspections of 503A facilities, rather than complying
with current statute
– FDA still intends to include CGMPs on Form FDA-483s, potentially for 503A
pharmacies
20
Recent Compounding Activities
•
FDA released a guidance document on Insanitary Conditions at Compounding
Facilities on August 4, 2015 which provides:
–
–
–
–
•
Examples of insanitary conditions
Procedures that compounding facilities should employ to ensure that they do not
have insanitary conditions and that they are capable of producing sterile drug
products
Actions that compounding facilities should take if they identify insanitary conditions
at their facilities
Potential FDA regulatory actions if insanitary conditions are not adequately corrected
APhA will be commenting by the October 3, 2016 deadline. In general, draft
guidance aligns current USP <797> and <800>, and CGMP standards
•
APhA also sent comments with other pharmacy associations requesting a five-year
delay in enforcement (until July 1, 2021) for State Boards of Pharmacy that may
adopt USP <800>
21
Biosimilars
•
Naming
–
–
•
APhA supports naming that, where possible, is consistent with that of small-molecule and generic
drugs
APhA submitted letters in opposition to S. 2700 supporting USP’s quality standards, which include
naming
• S. 2700 would give FDA additional flexibility in naming, including the use of a suffix
Labeling
–
–
–
August 2016: APhA submitted comments in response to FDA biosimilar product labeling guidance
The guidance included product identification practices (i.e. when to use the core name, biosimilar
product name, or more than one product name), inclusion of clinical study information, inclusion of
a statement of biosimilarity, and differences between labeling for safe and effective use
APhA gained member feedback from our biosimilars work group
• Comments supported consistent labeling where possible, discouraged the inclusion of a
statement of biosimilarity and expressed concerns regarding the clarity of labeling, especially
where more than one product name is used in a single section
22
Generic Drug Labeling
•
In July, FDA issued draft guidance that clarified the process of
updating a generic drug label with the reference product is no
longer on the market
•
As drafted, generic drug labels could potentially vary from other
generic drugs for the same reference product
– The timeline and expectations associated with labeling updates
was not clear
– APhA submitted ANDA labeling comments on September 8, 2016
expressing concerns regarding labeling variability between
generic products and emphasized the need for clear
communication
23
DQSA: Track and Trace
Additional Provisions for FDA:
Phase 1: Lot
Level
Traceability
Phase 2:
Product
Identifier (PI)
• Authorized trading
partner verification
(1/15)
• Suspect/illegitimate
product
identification and
notification (3/16)
• Transaction data
(1/15 & 3/16)
•Manufacturers add PI
to unit/case, and build
a database (11/17)
•Re-packagers add PI
to unit/case (11/27/18)
•Wholesaler
transactions with
identified products
(11/19)
•Dispenser transactions
with identified
products (11/20)
Phase 3:Unit
Level
Traceability
• Unit-level
traceability for all
supply chain
stakeholders (11/23)
• Track and
exchange unit-level
serialized data
(11/23)
• Small pharmacy technology
assessment on packagelevel tracing (2020)
• Establish and evaluate pilot
projects on enhancing
supply chain safety/security
(2020)(initial steps underway)
• Regulations establishing
enhanced drug distribution
security system for
interoperable electronic
tracing of product at the
package level (2021)
• Final guidance on
interoperable data
exchange standards for
secure package level
product tracing (2022)
24
Third-party Logistics Provider (3PL) and Wholesaler
Licensure
• DSCSA required FDA to issue 3PL and wholesaler licensure standards by
November 2015
– FDA intends to issue a proposed rule by December 2016
– FDA has yet to finalize 2014 draft guidance on the issue
• Delayed regulations are creating uncertainty amongst states and
members of the supply chain regarding the content and validity of state
licensure standards
• In August, OptumRX sent a letter to pharmacies stating that, to receive
reimbursement, pharmacies must purchase medications dispensed to
OptumRX participants from a Verified-Accredited Wholesale Distributor
(VAWD), which is an NABP-accreditation
25
Medical Devices/ Testing
•
•
CMS and FDA focusing on harmonizing oversight of laboratory developed tests
– Pharmacists can perform CLIA-waived tests, although reimbursement issues still exist
Infectious Disease Testing
– FDA Microbiology Device Panel discussed OTC infectious disease tests in August 2016
o FDA discussing tests that are CLIA-waived, which in many states pharmacists can have a
role in administering and interpret the results
o APhA submitted comments discussing the pharmacists role in patient care and in antibiotic
stewardship; also discussed labeling improvements and result reporting
•
Pharmacogenomics/ Genetic Testing
– APhA submitted comments in response to FDA’s March 2016 public workshop on the return
of genetic test results
o Comments highlighted the pharmacist’s role and education related to pharmacogenomics
–
APhA receives feedback from a 20+ member pharmacogenomics/ genetic tests work
group
26
HHS Nondiscrimination Final Rule
On May 18, 2016, HHS released a final rule regarding nondiscrimination in most health
care programs and activities
• The rule is a result of the Affordable Care Act (Section 1557) which prohibits
discrimination on the basis of race, color, national origin, sex (including gender
identity), age, or disability in health care programs and activities
• Effective date is July 18, 2016 and several requirements (i.e. notice) must be
satisfied within 90 days of July 18
Covered entities (e.g., pharmacies) must:
• Submit assurance of compliance (w/ Section 1557) if applying for Federal
financial assistance
• If the covered entity employs 15 or more persons it must: (1) Designate a
responsible employee to comply with and carry out the Rule’s requirements; and
(2) Adopt grievance procedures
27
HHS Nondiscrimination Final Rule: Notice Samples
Portion of sample posting:
•
[Entity] provides free aids and services to people with disabilities to communicate effectively with
us, such as:
– Qualified sign language interpreters
– Written information in other formats (large print, audio, accessible electronic formats, other
formats)
•
[Entity] Provides free language services to people whose primary language is not English, such as:
– Qualified interpreters
– Information written in other languages
•
If you believe that [Entity] has failed to provide these services or discriminated in another way on
the basis of race, color, national origin, age, disability, or sex, you can file a grievance with:
[Contact information for civil right coordinator]
Tagline example: ATTENTION: If you speak [insert language], language assistance services, free of
charge, are available to you. Call 1-xxx-xxx-xxxx (TTY: 1-xxx-xxx-xxxx).
28
EPA Proposed Rule: Hazardous Waste Pharmaceuticals
•
•
•
September 2015: EPA released the proposed rule “Management Standards for Hazardous Waste Pharmaceuticals”
– Unifies requirements for health care facilities, which includes pharmacies, that generate more than 100kg of hazardous
waste or 1kg of acute hazardous waste monthly;
– Provides fewer requirements for facilities generating less waste are “conditionally exempt small quantity generators”
(CESQGs)
– Outlines hazardous waste determinations, disposal options including a sewering ban, shipping requirements, training
requirements, and on-site storage (among others)
Pharmacies (unless CESQGs) will need to:
– Determine whether pharmaceutical waste is hazardous
– Determine their generator category and submit one-time notice to EPA
– Sort potentially creditable hazardous waste and non-creditable hazardous waste
• Potentially creditable waste may be disposed of using a pharmaceutical reverse distributor or treatment,
storage & disposal facility (TSDF)
• Non-creditable hazardous waste may be disposed of using a TSDF
– Stop sewering (including CESQGs)
– Adhere to specific storage, shipping and recordkeeping requirements
Not expected to be finalized in 2016
29
EPA Proposed Rule (Cont.)
APhA submitted comments addressing the following areas:
• Pharmaceutical definition: Recommended that EPA exempt dietary supplements and
pharmaceuticals with a radioactive component
• Hazardous Waste Pharmaceutical: Recommended development of a hazardous waste
pharmaceutical list and reconsider counting potentially creditable pharmaceuticals as
waste
• Residue: Requested EPA clarify exemptions
• Sewering ban: Recommended exempting run-off from cleaning
• Additional requests:
– Harmonize regulations with other federal agencies and their regulations; such as
DQSA/ DSCSA and DEA (e.g., disposal options for controlled substances)
– Increase education and awareness initiatives before the rule is effective
30
Fair Labor Standards Act (FLSA) Final Rule
•
•
•
•
On May 18, the Department of Labor (DoL) published the final rule, Defining and
Delimiting the Exemptions for Executive, Administrative, Professional, Outside Sales
and Computer Employees which details requirements, including salary levels, for
exemptions from the FLSA wage and overtime requirements
Generally, pharmacists, including pharmacy residents, are exempt from overtime
pay requirements because they qualify as a “learned professional” which is a type
of professional eligible for executive, administrative, and professional (EAP)
exemption
– EAP exempt employees are entitled to a minimum salary but not overtime pay
The final rule increases the EAP exemption’s minimum salary requirement from
$455/week to $913/week (i.e. from $23,660 to $47,476 annually)
– DoL will automatically increase the minimum salary level once every three years
Employers need to comply with the new minimum salary level by December 1, 2016
31
FLSA & Pharmacy Residents
• FLSA treats physicians, including medical residents, different from
other health care professionals such as pharmacists
• Under FLSA, physicians are not entitled to a minimum salary or
overtime pay
• APhA submitted comments to DoL and the Senate HELP
Committee requesting that the final rule treat pharmacy residents
like medical residents or at a minimum, delay the implementation
date; unfortunately DoL did not adopt APhA’s suggestions
• APhA remains concerned that pharmacy resident programs will
suffer because they cannot satisfy the new minimum salary level
32
Recent APhA Comment Letters
Submitted
•
6/27 Medicare Program; Merit-Based Incentive Payment System and Alternative Payment Model
Incentive under the Physician Fee Schedule, and Criteria for Physician-Focused Payment Models;
Proposed Rule (CMS)
•
7/18 Hospital and Health System Compounding Under the Federal Food, Drug, and Cosmetic Act (FDA)
•
7/18 Prescription Requirement Under Section 503A of the Federal Food, Drug, and Cosmetic Act (FDA)
•
8/2 Biosimilar Labeling Guidance (FDA)
•
8/15 Medicare & Medicaid Programs; Hospital and Critical Access Hospital (CAH) Changes To Promote
Innovation, Flexibility, and Improvement in Patient Care; Proposed Rule (CMS)
•
8/22, PDUFA VI Proposed Commitment Letter (FDA)
•
8/22 Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of
Annual Needs for the List I Chemicals Ephedrine, Pseudophedrine, Phenylpropanolamine for 2017 (DEA)
•
9/6 Medicare Physician Fee Schedule; Proposed Rule (CMS)
•
9/6 Request for Information: Opioid Analgesic Prescriber Education and Training Opportunities To Prevent
Opioid Overdose and Opioid Use Disorder (HHS)
•
9/8 Updating Abbreviated New Drug Application Labeling After the Marketing Application for the
Reference Listed Drug Has Been Withdrawn; Draft Guidance for Industry (FDA)
•
9/16 Microbiology Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting (FDA)
33
Upcoming APhA Regulatory Activities
Upcoming/ Comments due soon:
•
Procedure for Inspections of Entities that are Seeking to Compound Human Drugs in Accordance
with Section 503A of the Federal Food, Drug, And Cosmetic Act (FD&C Act), No Due Date (Notice)
•
Insanitary Conditions at Compounding Facilities, 10/3 (Draft Guidance)
•
HHS Notice of Benefit and Payment Parameters for 2017, 10/3 (Proposed Rule)
•
Use of Public Human Genetic Variant Databases To Support Clinical Validity for Next Generation
Sequencing-Based In Vitro Diagnostics, 10/6 (Draft Guidance)
•
Use of Standards in FDA Regulatory Oversight of Next Generation Sequencing (NGS)-Based In Vitro
Diagnostics (IVDs) Used for Diagnosing Germline Diseases, 10/6 (Proposed Rule)
•
Adapting Regulatory Oversight of Next Generation Sequencing-Based Tests, 10/6 (Public Workshop)
•
Compounded Drug Products that are Essentially Copies of a Commercially Available Drug Product
under the Federal Food, Drug, and Cosmetic Act (503A), 10/11 (Draft Guidance)
•
Compounded Drug Products that are Essentially Copies of Approved Drug Products under the
Federal Food, Drug, and Cosmetic Act (503B), 10/11 (Draft Guidance)
•
Dietary Supplements: New Dietary Ingredient Notifications and Related Issues, 10/11 (Draft
Guidance)
34
ADVOCACY & GETTING AND
STAYING INVOLVED!
35
Messaging Focus
•
Print and radio ads targeted to DC
policymakers
– Not a consumer campaign
•
Overall message is the need for Seniors’
access to healthcare
•
Some ads highlighted different problems
– E.g. urban - difficult to get appointments
and need for multiple bus lines
•
Some highlighted rural issues – e.g.
physician miles away
36
Messaging Focus
• Focused on different
services and needs
(e.g. diabetes, heart
conditions, asthma)
37
38
Pharmacy’s Next Steps
• Keep pharmacy unified
• Incorporate in solutions and offerings policymakers and
decision-makers’ concerns and what they value
‒ E.g. transitions of care, movement towards coordinated
care and new delivery models, addressing high cost items
• Lessen resistance by other health care providers
‒ States are having success at gaining support from other
professions
39
39
Pharmacy’s Next Steps
• Take advantage of state laws and actions (e.g. individual
Medicaid programs and health exchanges)
• Continue to demonstrate value
‒ Favorable quality/patient outcomes
‒ Impact on cost
• Highlight evidence and continue research
‒ As robust as possible but don’t let the perfect be an enemy
‒ Data is important but may not need to be in peer-reviewed
literature
40
APhA Advocacy Resources
APhA: PharmacistsProvideCare.com
•
Join the Campaign!
–
State-specific information
•
Fact Sheets
–
Making the case
–
Infographics
–
Public opinion polls
–
Scope of practice
•
Student Tool Kit
•
Supporter Engagement
–
Monthly Newsletters
–
Letters to Members of Congress
–
Advocacy Alerts
•
Messaging
–
E.g., FAQ
–
–
Social Media efforts - videos
Pharmacists’ Involvement Needed!
41
APhA Provider Status Activities
www.pharmacistsprovidecare.com
•
•
•
•
Messaging, stories and profiles highlighting pharmacists’ services
SHARE YOUR STORY! (and good outcomes)
Identifying other health care providers supportive of pharmacists
You don’t have to go to Washington DC to make a difference
– Politics is local!
42
Questions
?
Stacie S. Maass, BSPharm, JD
SVP, Pharmacy Practice and Government Affairs
American Pharmacists Association
Ph. 202-429-7533
[email protected]
43